154 related articles for article (PubMed ID: 29880172)
1. Elevated PAPP-A levels in lean patients with polycystic ovary syndrome.
Öztürk M; Öktem M; Altinkaya SÖ; Öktem EÖ; Elbeg Ş; Erdem A; Erdem M
Taiwan J Obstet Gynecol; 2018 Jun; 57(3):394-398. PubMed ID: 29880172
[TBL] [Abstract][Full Text] [Related]
2. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Küçük M; Altınkaya SÖ; Nergiz S; Sezer SD; Yüksel H; Bağlı İ; Yıldız G
Gynecol Endocrinol; 2014 Jun; 30(6):423-7. PubMed ID: 24628003
[TBL] [Abstract][Full Text] [Related]
5. Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome.
Erol O; Özel MK; Ellidağ HY; Toptaş T; Derbent AU; Yılmaz N
J Obstet Gynaecol; 2017 Jul; 37(5):633-638. PubMed ID: 28319674
[TBL] [Abstract][Full Text] [Related]
6. Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.
Rasool SUA; Ashraf S; Nabi M; Rashid F; Fazili KM; Amin S
Diabetes Metab Syndr; 2019; 13(3):2098-2105. PubMed ID: 31235143
[TBL] [Abstract][Full Text] [Related]
7. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
8. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
Glueck CJ; Morrison JA; Friedman LA; Goldenberg N; Stroop DM; Wang P
Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
[TBL] [Abstract][Full Text] [Related]
9. Apelin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Altinkaya SÖ; Nergiz S; Küçük M; Yüksel H
Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():168-72. PubMed ID: 24642195
[TBL] [Abstract][Full Text] [Related]
10. Clinical and metabolic characteristics of Turkish adolescents with polycystic ovary syndrome.
Ates S; Aydın S; Ozcan P; Soyman Z; Gokmen Karasu AF; Sevket O
J Obstet Gynaecol; 2018 Feb; 38(2):236-240. PubMed ID: 28920502
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between the triglyceride/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome].
Roa Barrios M; Arata-Bellabarba G; Valeri L; Velázquez-Maldonado E
Endocrinol Nutr; 2009 Feb; 56(2):59-65. PubMed ID: 19627713
[TBL] [Abstract][Full Text] [Related]
12. Assessing cardiovascular risk in Mediterranean women with polycystic ovary syndrome.
Rizzo M; Longo RA; Guastella E; Rini GB; Carmina E
J Endocrinol Invest; 2011 Jun; 34(6):422-6. PubMed ID: 20959718
[TBL] [Abstract][Full Text] [Related]
13. Metabolic syndrome in Greek women with polycystic ovary syndrome: prevalence, characteristics and associations with body mass index. A prospective controlled study.
Kyrkou G; Trakakis E; Attilakos A; Panagopoulos P; Chrelias C; Papadimitriou A; Vaggopoulos V; Alexiou E; Mastorakos G; Lykeridou A; Kassanos D; Papaevangelou V; Papantoniou N
Arch Gynecol Obstet; 2016 Apr; 293(4):915-23. PubMed ID: 26615602
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory and endothelial markers in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Alexandraki K; Piperi C; Protogerou A; Katsikis I; Paterakis T; Lekakis J; Panidis D
Eur J Clin Invest; 2006 Oct; 36(10):691-7. PubMed ID: 16968464
[TBL] [Abstract][Full Text] [Related]
15. Galanin and glypican-4 levels depending on metabolic and cardiovascular risk factors in patients with polycystic ovary syndrome.
Altinkaya SO
Arch Endocrinol Metab; 2021 Nov; 65(4):479-487. PubMed ID: 33740336
[TBL] [Abstract][Full Text] [Related]
16. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
[TBL] [Abstract][Full Text] [Related]
17. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
18. Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.
Daskalopoulos G; Karkanaki A; Piouka A; Prapas N; Panidis D; Gkeleris P; Athyros VG
Curr Vasc Pharmacol; 2015; 13(6):788-800. PubMed ID: 25600030
[TBL] [Abstract][Full Text] [Related]
19. Elevated thrombin activatable fibrinolysis inhibitor levels in women with polycystic ovary syndrome.
Güldaş M; Altinkaya SÖ; Nergiz S; Demircan-Sezer S; Yüksel H
Gynecol Endocrinol; 2015 Jul; 31(7):536-9. PubMed ID: 26220768
[TBL] [Abstract][Full Text] [Related]
20. Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome.
Moradi S; Mollabashi M; Kerman SR
Gynecol Endocrinol; 2011 Jul; 27(7):480-5. PubMed ID: 20836727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
